Molecular Formula | C25H31F3O5S |
Molar Mass | 500.57 |
Density | 1.32±0.1 g/cm3(Predicted) |
Melting Point | 275 °C |
Boling Point | 568.3±50.0 °C(Predicted) |
Specific Rotation(α) | D +30° (c = 0.35) |
Flash Point | 288.4°C |
Solubility | DMSO 100 mg/mL ;Water <1 mg/mL; Ethanol 5 mg/mL |
Vapor Presure | 1.52E-14mmHg at 25°C |
Appearance | White Solid |
Color | white |
Merck | 14,4211 |
pKa | 12.53±0.70(Predicted) |
Storage Condition | Store at RT |
Refractive Index | 31 ° (C=1, Dioxane) |
MDL | MFCD00866007 |
Physical and Chemical Properties | Crystalline, melting point 272-273 °c (decomposition). ^[α]D 30 °(C = 0.35). |
In vitro study | In human lung fibroblasts, Fluticasone propionate(1 pM) inhibited the constitutive and TGF-β-induced expression of α-SMA. Fluticasone propionate blocks nuclear translocation of the pro-inflammatory transcription factor NF-κB induced by TNF-α in human lung fibroblasts. Fluticasone propionate inhibits IL-13 (tyrosine kinase 2,STAT1,STAT3,STAT6, mitogen-activated protein kinase)-induced activation of the Janus kinase/STAT pathway in the early stages of lung fibroblast differentiation. In mildly or fully differentiated myofibroblast cultures, Fluticasone propionate still exhibited potential anti-inflammatory activity, although it only inhibited phosphorylation of tyrosine kinase 2. In early and mildly differentiated myofibroblasts, Fluticasone propionate inhibited constitutive and TGF-β-induced expression of α-smooth muscle actin, which is a major marker of myofibroblast differentiation. Fluticasone propionate exhibited an additional powerful anti-inflammatory effect, reducing the nuclear translocation of myofibroblast NF-κB independent of its degree of differentiation. Fluticasone propionate inhibited allergen-induced T cell proliferation, expression of IL-3,IL-5, and GM-CSF mRNA, and secretion of the corresponding proteins in a concentration-dependent manner. Fluticasone propionate significantly inhibited allergen-induced T-cell production of asthma-related cytokines. |
In vivo study | In horses, Fluticasone propionate administration after induction of severe eye deterioration resulted in complete resolution of clinical symptoms, normalization of pulmonary function tests and a significant decrease in bronchoalveolar neutrophil lavage (BAL). |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 2 |
RTECS | BV7980000 |
HS Code | 29372900 |
Toxicity | LD50 oral in rat: > 2gm/kg |